Key Takeaways
- Werewolf Therapeutics (HOWL) entered into an all-stock merger agreement with Ambros Therapeutics, creating a combined entity that will trade under the ticker “AMBX” on Nasdaq
- The merged company successfully raised $150 million through a private placement round jointly led by RA Capital Management and Janus Henderson Investors
- The new entity will prioritize development of neridronate, a therapeutic candidate for Complex Regional Pain Syndrome Type 1 (CRPS-1), a condition lacking FDA-approved treatment options
- In a concurrent transaction, Werewolf divested preclinical assets to EMD Serono for $28 million in immediate payment, with an additional $5 million contingent on technology transfer completion
- Shares of HOWL climbed 127% during Friday’s premarket session, reaching $0.9780
Shares of Werewolf Therapeutics (HOWL) experienced a dramatic 127% spike in premarket trading Friday, climbing to $0.9780, following dual announcements that reshape the company’s strategic direction.
Werewolf Therapeutics, Inc., HOWL
The primary development involves an all-stock merger agreement with Ambros Therapeutics. Following completion, the unified organization will adopt the Ambros Therapeutics identity and commence trading on Nasdaq using the symbol “AMBX.”
Concurrent with the merger announcement, both entities disclosed a $150 million private placement round. The offering exceeded initial expectations and was jointly anchored by RA Capital Management and Janus Henderson Investors, with additional participation from Aberdeen Investments, Adage Capital Partners and Balyasny Asset Management.
Management projects the new capital will sustain corporate operations through the anticipated topline data readout from the pivotal CRPS-RISE Phase 3 clinical trial in 2028. The merged entity anticipates its financial runway will last into early 2029.
Addressing a Significant Unmet Medical Need
The strategic rationale behind the combination centers on neridronate, an investigational therapeutic candidate being studied for patients diagnosed with warm CRPS-1. Approximately 65,000 individuals receive a CRPS-1 diagnosis annually in the United States, yet the condition currently has no FDA-approved therapeutic interventions.
Neridronate has already secured FDA Breakthrough Therapy, Fast Track and Orphan Drug designations. The compound received approval in Italy for CRPS and related indications and has been administered to approximately 600,000 patients in that country.
According to Ambros Therapeutics, the company’s intellectual property estate, when combined with the Orphan Drug designation, may provide U.S. market exclusivity extending through 2045.
The transaction assigns Ambros an implied valuation of $500 million. Werewolf carries a pre-financing valuation of $47.5 million. Upon transaction closure, ownership of the combined company is projected to consist of approximately 71.7% for Ambros shareholders, roughly 6.8% for Werewolf shareholders, and about 21.5% for private placement participants.
Subject to shareholder approval, the merger is anticipated to finalize during the first quarter of 2027.
EMD Serono Acquires Werewolf’s Preclinical Portfolio
Through a distinct agreement, Werewolf established an asset purchase arrangement with EMD Serono Research & Development Institute, an affiliate of Merck KGaA (MKKGY), executed on August 14 and revealed in an August 20 regulatory filing.
The arrangement stipulates EMD Serono will provide $28 million in upfront consideration plus an additional $5 million following successful technology transfer. The transaction encompasses Werewolf’s preclinical INDUCER platform alongside select INDUKINE assets.
Werewolf preserved all rights necessary to continue advancing its WTX-124 and WTX-330 clinical development programs. EMD Serono additionally provided Werewolf with an exclusive license to specific transferred patent rights supporting those ongoing programs.
During Friday’s premarket session, HOWL was changing hands at $0.9780, representing a 127% gain.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
